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doi:10.1016/j.kjms.2011.10.005Abstract Non-alcoholic fatty liver disease is associated with an increased risk of metabolic
and cardiovascular diseases. Whether the severity of fatty liver on ultrasound correlates with
metabolic or cardiovascular risk remains unclear. A total of 1000 people receiving health exam-
inations were enrolled, and 126 were excluded due to the presence of HBsAg, anti-HCV, known
hepatic disorders or alcohol use (>140 g/wk). Significant fatty liver consisted of moderate and
severe fatty liver on ultrasound. The definition of central obesity was modified to a waist
circumference of >90 cm in men and >80 cm in women. Framingham risk score was used to
estimate the risk of cardiovascular disease. A total of 874 subjects (485 women and 388
men with a mean age of 52.07  11.68 years) were included in the final analysis. By using
logistic regression analyses stratified by gender, the odds ratio for the prevalence of diabetes
mellitus, metabolic syndrome and risk of cardiovascular disease increased with increasing fatty
liver status in both genders (p  0.001). The difference was not only present between individ-
uals with fatty liver vs. non-fatty liver but also between the mild fatty liver and significant
fatty liver groups (p < 0.05). In conclusion, the severity of fatty liver on ultrasound could
be useful for the risk stratification of metabolic syndrome, diabetes mellitus and cardiovas-
cular disease in clinical practice.
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Non-alcoholic fatty liver disease (NAFLD) is defined as
radiological or pathological confirmation of hepatic stea-
tosis with the clinical exclusion of excessive alcohol intake
and other known chronic liver diseases. It is an emerging
disease worldwide and has become the leading cause of
chronic liver disease in Western countries. In Taiwan, the
prevalence is also increasing and the results of a number of
studies have been published (Table 1) [1e11]. This rise is in
parallel with the obesity and diabetes mellitus pandemics,
which are accompanied by the Westernization of food and
lifestyle [12e14]. The hepatic histology varies widely in
NAFLD, from simple steatosis to non-alcoholic steatohepa-
titis or fibrosis with the potential to develop end-stage liver
disease, including cirrhosis and liver cancer [15e18]. NAFLD
has also been recognized as the hepatic manifestation of
metabolic syndrome [19,20], which is a surrogate of
cardiovascular risk [21]. Recent studies have indicated that
patients with NAFLD have increased risks of metabolic
syndrome, diabetes mellitus and cardiovascular disease
(CVD) [22e24]. Of particular note is that NAFLD patients
have higher all-cause mortality than healthy controls [25].
Further studies on different aspects of NAFLD are thereforeTable 1 Researches of non-alcoholic fatty liver disease in Taiw
Author (year) Study design Number of patients
Chiang (2010) Case series 724 without CVD NAFLD is
risk, esp
increased
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Chen (2010) Case series 295 NAFLD w
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Hsieh (2009) Case series 2539 Metaboli
liver fun
Wang (2009) Case series 170 NAFLD patients Serum AL
of caroti
Tsai (2008) Case series 876 Metaboli
independ
Chu (2007) Case series 144 TNF-alph
Huang (2007) Case series 111 obese patients Presence
and high
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Hsiao (2007) Case series 16,486 The pres
correlate
of hyper
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Chen (2007) Case series 3260 adults NAFLD ap
ALT in Ta
associate
Chen (2006) Case series 3245 adults NAFLD is
diabetes
hypertrig
Abbreviations: ALT Z alanine aminotransferase, BMI Z body mass in
CVDZ cardiovascular disease, NAFLDZ non-alcoholic fatty liver dise
factor.urgently needed in order to understand more about this
global health threat.
In patients with NAFLD, the leading causes of fatality are
liver complications and CVD [26]. Although liver biopsy
remains the gold standard for the diagnosis and predicting
prognosis of liver complications in NAFLD, there are several
disadvantages, such as possible bleeding complications and
the small sample size compared with the whole liver or
interobserver variability [27,28]. Readily available labora-
tory tests, aspartate aminotransferase-to-platelet ratio
index (APRI) and aspartate aminotransferase/alanine
aminotransferase (AST/ALT) ratio are simple non-invasive
indices that have been applied to predict significant
fibrosis in patients with NAFLD [29,30]. Non-invasive
methods to predict the risk of metabolic or CVD in patients
with NAFLD, however, are rare. A recent study demonstrated
that the severity of fatty liver on ultrasound was associated
with the risk of metabolic syndrome [31]. Whether the
severity of fatty liver could be extrapolated to stratify the
risk of liver complications or CVD in NAFLD patients remains
unknown and deserves additional studies. For this reason,
we have investigated the association between fatty liver
severity and metabolic risks and hepatic complications in
a large cohort of people receiving health examinations.an.
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Patients and methods
A total of 1000 people were enrolled from the health
examination center of the Buddhist Tzu Chi General
Hospital between October 2007 and December 2008.
Demographic, anthropometric, clinical and laboratory data
were obtained from each individual. A well-trained study
nurse questioned the patients on their drug and alcohol
history. Among these, 126 patients were excluded due to
the presence of hepatitis-B-virus antigen (HBsAg),
hepatitis-C antibody (anti-HCV), known hepatic disorders or
alcohol use (>140 g/wk). Framingham risk score, APRI and
AST/ALT ratio were adopted to predict the risk of CVD and
the severity of hepatic fibrosis.Clinical features and biochemical examinations
We collected information on age, sex, past history of
hypertension and diabetes mellitus, history of drug or
alcohol use, body mass index (BMI), waist circumference,
systolic blood pressure (SBP), diastolic blood pressure
(DBP), ALT, AST, cholesterol, triglyceride, high-density
lipoprotein cholesterol (HDL-C), low-density lipoprotein
cholesterol (LDL-C), fasting plasma glucose, glycated
hemoglobin (HbA1c), hemoglobin, white blood cell and
platelet count. BMI was calculated as weight in kilograms
divided by height in square meters. Metabolic syndrome
was determined by using the National Cholesterol Educa-
tion Program, Adult Treatment Panel III (2002 panel)
guidelines. It was defined as the presence of three or more
of the following criteria: central obesity, high blood pres-
sure (130/85 mmHg or antihypertensive treatment),
decreased HDL-C (<40/50 mg/dl in men/women),
increased fasting glucose 110 mg/dl or glucose-lowing
drug or previously diagnosed diabetes mellitus and
increased triglyceride 150 mg/dl under fasting conditions
or fibrate or nicotinic acid therapy [32]. Central obesity was
modified to waist circumference >90 cm in men and
>80 cm in women, according to the Department of Health
in Taiwan. An automated Sysmex XE-2100 hematology
analyzer (Sysmex, Kobe, Japan) assessed the hemogram,
and biochemical data were measured using an autoanalyzer
(ROCHE ANALYTICS; Roche Professional Diagnostics, Penz-
berg, Germany).Ultrasound examination of the liver
All sonograms were obtained from the same machine
(LOGIQ-5, GE, Medical System LTD, Seoul, Korea) with
a 4 MHz electronic probe. The technical parameters,
including gain adjustment and use of tissue harmonics,
were optimized on a case-by-case basis. The severity of
fatty liver was recorded as non-fatty liver, mild, moderate
or severe fatty liver according to the findings of bright
liver, hepatorenal echo contrast, the blurring of vessels
and deep attenuation of ultrasound signal [33]. Significant
fatty liver consisted of moderate and severe fatty liver on
ultrasound.Framingham risk score and aspartate
aminotransferase-to-platelet ratio index
Using the information on age, gender, LDL-C, blood pres-
sure, the presence of diabetes and smoking, we were able
obtain the estimated and comparative coronary heart
disease risk over a period of 10 years based on the Fra-
mingham experience in people between 30 and 74 years at
baseline [34]. The relative risk was calculated by dividing
the estimated risk by the comparative risk, which is defined
as the average risk of coronary heart disease over a period
of 10 years in age and gender-matched subjects. APRI was
calculated using the following formula [35]:
AST

IU=mL

upper normal limit
 100=platelet count 109=L:
Study design
On the basis of the severity of fatty liver on ultrasound,
patients who were enrolled were divided to three groups as
follows:
 significant fatty liver group including subjects with
moderate or severe fatty liver;
 mild fatty liver group; and
 control (non-fatty liver) group.
The three groups were compared in terms of the pres-
ence of diabetes, metabolic syndrome, the risk of CVD
assessed by Framingham risk score, the presence of hepatic
inflammation or fibrosis determined by elevated ALT levels
(men >31 IU/L and women >20 IU/L) and APRI value,
respectively [36].
Ethical considerations
The study was performed in accordance with the principles
of the 1975 Declaration of Helsinki and approved by the
Buddhist Tzu-Chi General Hospital Ethical Committee (98-
IRB-018-X). Written informed consent was obtained from
each person who took part.
Statistical analysis
Mean and standard deviation were calculated for continuous
variables. Percentage was used for categorical variables. In
univariate analysis, we compared all the variables between
patientswithandwithout fatty liver andpatientswithmildand
significant fatty liver. Chi-squared and Student t tests were
used to compare the distributions of frequency and the means
among different groups, respectively. Logistic regression
analysiswasused toestimate theodds ratioofhavingdiabetes,
metabolic syndrome, relative cardiovascular risk, elevated
ALT levels and fibrosis severity in three different ways:
 first, we defined non-fatty liver, mild fatty liver and
significant fatty liver as an ordinal variable and deter-
mined the odds ratios (ORs) of each increment of the
severity of fatty liver;
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with and without fatty liver;
 third, the ORs were derived from comparing patients
with mild and significant fatty liver.
Statistical analyses were performed using SAS 9.1 (SAS
Institute Inc., Cary, NC, USA). A p value of <0.05 was
considered statistically significant.
Results
Demographic data and comparison between patient
and control groups
A total of 874 subjects (485 women and 388 men with
a mean age of 52.07  11.68 years) were included in the
final analysis. The prevalence of diabetes and metabolic
syndrome were 8.4% and 20.6%, respectively.
Based on the finding of fatty liver on ultrasound, the
patients were divided to two groups: fatty liver (52.9%,
462/874); and non-fatty liver (47.1%, 412/874). The indi-
viduals with fatty liver had a higher mean age compared to
those without (54.00  10.69 vs. 50.34  12.51, p <0.001).
The percentage of men was higher in the fatty liver group
compared with the non-fatty liver group (50.9 % vs. 37.1%,
p < 0.001). Furthermore, the prevalence of diabetes,
central obesity or the components of metabolic syndrome
were significantly higher in fatty liver than the non-fatty
liver group. In addition, higher BMI, waist circumference,
relative risk of CVD, SBP, DBP, triglyceride, LDL-C, AST, ALT
and APRI were noted in the fatty liver group, along with
lower HDL-C and AST/ALT ratios compared with the control
(non-fatty liver) group.
According to the severity of fatty liver found during
ultrasound, the fatty liver group was divided into two
groups: mild fatty liver (MFL, 63.9%) and significant fatty
liver (SFL, 36.1%). Compared to the MFL group, the
percentage of men, individuals with diabetes, central
obesity, items of metabolic syndrome or history of smoking
was significantly higher in the SFL group. In addition, higher
BMI, waist circumference, relative risk of CVD, high blood
pressure, triglyceride, AST, ALT and APRI readings, and
lower HDL-C and AST/ALT ratio were noted in the SFL
group. There was no difference in age, platelet count, LDL-
C level and the presence of LDL-C >130 mg/dl between the
MFL and SFL groups (Table 2).
Prevalence of metabolic diseases
In terms of diabetes, if defining the severity of fatty liver as
an ordinal variable, the OR for every increment in severity
was 3.3 in women (95% confidence interval (CI) 1.95.8)
and 2.9 in men (95% CI 1.94.6). Furthermore, the risk was
significantly higher in patients with fatty liver compared to
non-fatty liver as well as in those with SFL compared to
MFL. For the metabolic syndrome, the OR for every incre-
ment in fatty liver severity was 3.3 in women (95% CI
2.34.6) and 3.7 in men (95% CI 2.65.3). The risk was
significantly higher in patients with fatty liver compared to
without, as well as being significantly higher in those with
SFL compared to MFL (p < 0.01) (Table 3).Risk of cardiovascular disease
The model of the Framingham risk score could not be used
to predict cardiovascular risk in people aged 30 to 74 years
at baseline, so 770 subjects who belonged to this age group
were included in the analyses. Increased risk of CVD was
defined as a relative risk >1. The OR for every increment of
fatty liver severity was 2.3 in women (95% CI 1.43.5) and
2.7 in men (95% CI 1.74.1) (Table 3). The CVD risk also
increased in patients with fatty liver compared to non-fatty
liver as well as in those with SFL compared to MFL
(p < 0.01) (Table 3).
Risk of elevated ALT levels and fibrosis
The elevated ALT levels were defined by the updated cut-
off values (men >31 U/mL and women >20 U/mL). Using
logistic regression analyses, the OR for every increment in
fatty liver severity was 1.4 in both men and women (95% CI
1.02.0). A significant difference was only present
between the fatty liver and non-fatty liver group, however,
and was not seen between MFL and SFL groups (Table 3).
APRI (S1 for cirrhosis or S0.5 for significant fibrosis)
and AST/ALT ratio (S0.8) had been used as clinical markers
of hepatic fibrosis in patients of NAFLD. The fatty liver
group had significantly higher APRI than the control group.
In addition, the SFL group had a higher APRI than the MFL
group (Table 2). Using stratified analysis, by gender and age
adjustment the likelihood of having APRIS0.5 or 1 was 1.8
(95% CI 1.12.9) and 5.5 (95% CI 1.323.6), respectively,
for every increment in fatty liver severity in women. The
difference was not present when comparing women with
fatty liver and those without or when comparing the MFL
and SFL groups. There was no obvious association between
the severity of fatty liver and APRI levels in men (Table 3).
In those with an AST/ALT ratio S0.8, the OR for every
increment in fatty liver severity was 0.3 in both men and
women (95% CI 0.20.4). A significant difference was
present when comparing patients with fatty liver and non-
fatty liver as well as those with MFL and SFL (Table 3).
Discussion
In this study, we demonstrated that the severity of fatty
liver as determined using ultrasound could be useful for the
risk stratification of CVDs in clinical practice. Furthermore,
we consistently confirmed that patients with NAFLD had
a higher risk of developing inherent metabolic diseases,
such as metabolic syndrome and diabetes. In addition to
this, the prevalence of metabolic diseases and the risk of
CVD trended to increase with the severity of fatty liver on
ultrasound. Unsurprisingly, those with a fatty liver on
ultrasound had a higher probability of hepatic inflammation.
NAFLD has been reported to be associated with diabetes
and metabolic syndrome. Our results consistently confirmed
that patients with fatty liver had an increased likelihood of
metabolic syndrome and diabetes than those without.
Moreover, patients with SFL on ultrasound had a higher
likelihood of having diabetes and metabolic syndrome
compared to those with MFL. This semiquantitative dose-
response relationship could provide solid evidence to
Table 2 Comparison of characteristics between patients with and without fatty liver and with different severities of fatty
liver.
Non-fatty liver
(n Z 412)
Fatty liver
(n Z 462)
p value Mild fatty liver
(n Z 295)
Significant fatty
liver (n Z 167)
p value
Gender
Women 259 (62.0) 227 (49.1) 160 (54.2) 67 (40.1)
Men 153 (37.1) 235 (50.9) <0.001 135 (45.8) 100 (59.9) 0.004
Age (years)
Mean  SD 50.34  12.51 54.00  10.69 <0.001 54.16  10.49 53.71  11.05 0.666
Smoking
No 389 (94.4) 428 (92.6) 279 (94.6) 149 (89.2)
Yes 23 (5.6) 34 (7.4) 0.288 16 (5.4) 18 (10.8) 0.034
Body mass indexa
Mean  SD 21.74  2.62 24.95  3.56 <0.001 24.08  3.30 26.48  3.49 <0.001
Waist conference (cm)
Women, mean  SD 74.48  6.99 81.50  9.08 <0.001 79.42  8.54 86.47  8.43 <0.001
Men, mean  SD 77.93  7.37 87.23  9.00 <0.001 85.27  8.21 89.88  9.27 <0.001
Central obesityb
No 360 (87.4) 277 (60.0) 204 (69.2) 73 (43.7)
Yes 52 (12.6) 185 (40.0) <0.001 91 (30.9) 94 (56.3) <0.001
Diabetes mellitusc
No 400 (97.1) 401 (86.8) 273 (92.5) 128 (76.7)
Yes 12 (2.9) 61 (13.2) <0.001 22 (7.5) 39 (23.4) <0.001
Increased fasting sugar leveld
No 383 (93.0) 366 (79.2) 254 (86.1) 112 (67.1)
Yes 29 (7.0) 96 (20.8) <0.001 41 (13.9) 55 (32.9) <0.001
Systolic blood pressure (mm Hg)
Mean  SD 118.95  16.23 124.64  16.52 <0.001 122.70  16.84 128.09  15.38 <0.001
Diastolic blood pressure (mm Hg)
Mean  SD 73.31  11.20 76.90  12.41 <0.001 75.57  12.44 79.27  12.03 0.002
High blood pressuree
No 296 (71.8) 258 (55.8) <0.001 186 (63.1) 72 (43.1) <0.001
Yes 116 (28.2) 204 (44.2) 109 (37.0) 95 (56.9)
Triglyceride (mg/dl)
Mean  SD 102.73  52.75 155.97  107.23 <0.001 140.45  72.45 138.38  146.47 <0.001
Triglyceride >150 mg/dl
No 352 (85.4) 276 (59.7) <0.001 193 (65.4) 83 (49.7) 0.001
Yes 60 (14.6) 186 (40.3) 102 (34.6) 84 (50.3)
HDL-C (mg/dl)
Mean  SD 58.13  15.49 49.15  13.01 <0.001 51.36  13.34 45.24  11.44 <0.001
Decreased HDL-Cf
No 327 (79.4) 277 (60.0) 193 (65.4) 84 (50.3)
Yes 85 (20.6) 185 (40.0) <0.001 102 (34.6) 83 (49.7) 0.001
LDL-C (mg/dl)
Mean  SD 118.34  31.43 130.82  32.05 <0.001 130.21  31.42 131.90  33.19 0.586
LDL-C >130 mg/dl
No 272 (66.0) 245 (53.0) 162 (54.9) 83 (49.7)
Yes 140 (34.0) 217 (47.0) <0.001 133 (45.1) 84 (50.3) 0.281
Relative risk of CVDg 0.52  0.31 0.70  0.39 <0.001 0.62  0.35 0.82  0.42 <0.001
(continued on next page)
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Table 2 (continued )
Non-fatty liver
(n Z 412)
Fatty liver
(n Z 462)
p value Mild fatty liver
(n Z 295)
Significant fatty
liver (n Z 167)
p value
ALT (IU/L)
Mean  SD 20.83  14.30 32.04  24.58 <0.001 28.11  22.13 38.98  27.10 <0.001
AST (IU/L)
Mean  SD 22.38  8.31 25.87  12.18 <0.001 24.37  10.08 28.51  14.88 <0.001
Platelet (109/L)
Mean  SD 244.63  58.14 248.96  57.84 0.271 250.72  59.72 245.84  54.39 0.385
AST/ALT ratio
Mean  SD 1.19  0.36 0.95  0.33 <0.001 1.02  0.35 0.82  0.24 <0.001
APRIh
Mean  SD 0.28  0.14 0.31  0.18 0.018 0.29  0.15 0.34  0.22 0.005
Abbreviations: ALT Z alanine aminotransferase, APRI Z aspartate aminotransferase-to-platelet ratio index, AST Z aspartate amino-
transferase, CHDZ coronary hear disease, HDL-CZ high-density lipoprotein cholesterol, LDL-CZ low-density lipoprotein cholesterol,
SD Z standard deviation.
a body mass index Z weight (kg)/height (m2).
b waist circumference >90 cm in men and >80 cm in women.
c fasting glucose 126 mg/dl or patient on glucose-lowing drug or previously diagnosed with diabetes mellitus.
d increased fasting glucose 110 mg/dl or patient on glucose-lowing drug or previously diagnosed with diabetes mellitus.
e systolic blood pressure >130 or diastolic blood pressure >85 mmHg or receiving antihypertensive treatment.
f HDL-C <40/50 mg/dl in men/women.
g relative risk is derived from dividing the estimated risk of CVD by the comparative risk that is defined as the average risk of CVD.
h APRI is derived from the formula of AST (U/L)/upper normal limit  100/platelet count (109/L).
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and diabetes.
Ultrasound, being cheap, readily available and without
the risk of radiation exposure, is the most common
modality by which NAFLD is diagnosed in clinical practice
[37,38]. Our results further confirmed that it could be used
as a tool to stratify the risk of metabolic syndrome and
diabetes in individuals with NAFLD.
A case-control study found that patients with NAFLD had
a higher prevalence of plaques and greater intima-media
thickness of the carotid arteries than controls [39]. Another
study proved the relationship between the severity of liver
histology and carotid atherosclerosis, regardless of classic
CVD risk factors [40]. In addition, patients with NAFLD are
reported to have an increased risk of CVD and all-cause
mortality compared to the general population [41]. The
identification of surrogates that could further stratify the
risk of CVD in patients with NAFLD is therefore clinically
important. For example, serum ALT level has been found to
be positively associated with the risk of carotid athero-
sclerosis in NAFLD patients. In this study, using Framingham
risk score we have gathered data showing that the severity
of fatty liver on ultrasound correlates with CVD risk. The
patients with SFL had the greatest likelihood of CVD
compared to healthy controls and those with MFL had
a lower risk than patients with SFL. On the basis of these
findings, even patients with MFL should be screened and
treated for the presence of other CVD risk factors.
Serum ALT has long been recognized as a marker of
hepatic inflammation. In patients who have no viral or
other known causes of hepatitis, elevated serum ALT level
is a clinical indicator of NAFLD, but is only found in
a portion of these patients [42]. Our data showed that thelikelihood of ALT elevation tended to increase with the
severity of fatty liver detected during ultrasound. This
suggests that hepatic steatosis could damage hepatocytes
through the “second hit” as opposed in the pathogenesis
of NAFLD [43]. Our earlier study indicated that NAFLD
patients with ALT elevation had an increased risk of
carotid atherosclerosis compared to those with normal
ALT levels, suggesting that serum ALT levels could serve
as a clinical marker that is predictive of CVD risk [44].
Taking these data together, our findings strengthen the
association between fatty liver, elevated ALT levels and
CVD risk.
APRI is a non-invasive marker that predicts the severity
of hepatic fibrosis in patients with chronic hepatitis C virus
infection, even in patients using hemodialysis [45,46].
Recent studies have further proved its use in the diagnosis
of other causes of hepatitis, such as hepatitis B virus
infection and NAFLD [47]. An AST/ALT ratio S0.8 was also
used to predict the presence of significant fibrosis in
patients with NAFLD. By using the AST/ALT ratio, we found
that the presence of significant fibrosis was less likely with
increasing fatty liver severity and that healthy controls
were more likely to have significant fibrosis. This result is
quite unreasonable in clinical practice. Further studies are
therefore warranted to determine whether the AST/ALT
ratio could be used to predict hepatic fibrosis in patients
with NAFLD. Where the APRI was >0.5 or 1, the presence
of significant fibrosis was increasingly likely with the
increasing severity of fatty liver in women but not in men.
This significant finding in women was not present when
comparing patients with fatty liver and those without as
well as comparing the MFL and SFL groups. For this reason,
the relationship between the clinical markers of hepatic
Table 3 Odds ratio of liver or non-liver related complication of non-alcoholic fatty liver disease among significant, mild fatty
liver and non-fatty liver groups by logistic regression analyses adjusted by age (every 10-year increment).
Fatty liver OR (95% CI) p value Age-adjusted OR (95% CI) p value
Non Mild Significant
Diabetes mellitus
Women
No 253 (97.7) 152 (95.6) 52 (77.6) 3.8 (2.2-6.4)a <0.001 3.3 (1.9-5.8)a <0.001
Yes 6 (2.3) 7 (4.4) 15 (22.4) 4.5 (1.8-11.4)b 0.001 3.7 (1.4-9.4)b 0.006
6.3 (2.4-16.2)c <0.001 5.8 (2.2-15.2)c <0.001
Men
No 147 (96.1) 121 (89.0) 76 (76.0) 2.7 (1.8-4.2)a <0.001 2.9 (1.9-4.6)a <0.001
Yes 6 (3.9) 15 (11.0) 24 (24.0) 4.9 (2.0-11.8)b <0.001 4.8 (2.0-11.8)b 0.001
2.5 (1.3-5.2)c 0.009 2.9 (1.4-6.1)c 0.004
Metabolic syndrome
Women
No 239 (92.3) 123 (77.4) 32 (47.8) 3.6 (2.6-5.0)a <0.001 3.3 (2.3-4.6)a <0.001
Yes 20 (7.7) 36 (22.6) 35 (52.2) 5.5 (3.2-9.4)b <0.001 4.7 (2.7-8.1)b <0.001
3.7 (2.0-6.9)c <0.001 3.6 (1.9-6.6)c <0.001
Men
No 145 (94.7) 100 (73.5) 55 (55.0) 3.4 (2.4-4.8)a <0.001 3.7 (2.6-5.3)a <0.001
Yes 8 (5.2) 36 (26.5) 45 (45.0) 9.5 (4.4-20.3)b <0.001 9.6 (4.4-20.6)b <0.001
2.3 (1.3-3.9)c 0.003 2.6 (1.5-4.6)c 0.001
ALT elevationd
Women
No 225 (86.8) 129 (81.1) 51 (76.1) 1.5 (1.1-2.0)a 0.021 1.4 (1.0-2.0)a 0.031
Yes 34 (13.1) 30 (18.9) 16 (23.9) 1.7 (1.0-2.7)b 0.034 1.6 (1.0-2.7)b 0.048
1.3 (0.7-2.7)c 0.394 1.3 (0.7-2.7)c 0.407
Men
No 135 (88.2) 113 (83.1) 79 (79.0) 1.4 (1.0-2.0)a 0.048 1.4 (1.0-2.0)a 0.040
Yes 18 (11.8) 23 (16.9) 21 (21.0) 1.7 (1.0-3.1)b 0.072 1.8 (1.0-3.3)b 0.048
1.3 (0.7-2.5)c 0.426 1.2 (0.6-2.3)c 0.620
RR S1.0e
Women
No 198 (94.3) 130 (92.2) 46 (75.4) 2.3 (1.5-3.6)a <0.001 2.3 (1.4-3.5)a <0.001
Yes 12 (5.7) 11 (7.8) 15 (24.6) 2.4 (1.2-5.0)b 0.014 2.3 (1.1-4.7)b 0.027
3.9 (1.7-9.0)c 0.002 3.8 (1.6-8.9)c 0.002
Men
No 129 (94.9) 113 (89.0) 69 (72.6) 2.7 (1.8-4.2)a <0.001 2.7 (1.7-4.1)a <0.001
Yes 7 (5.2) 14 (11.0) 26 (27.4) 4.1 (1.8-9.3)b 0.001 4.4 (1.9-10.2)b 0.001
3.0 (1.5-6.2)c 0.002 2.7 (1.3-5.5)c 0.009
APRIf S0.5
Women
No 250 (96.5) 149 (93.7) 58 (86.6) 2.1 (1.3-3.4)a 0.004 1.8 (1.1-2.9)a 0.026
Yes 9 (3.5) 10 (6.3) 9 (13.4) 2.5 (1.1-5.8)b 0.024 2.0 (0.9-4.7)b 0.094
2.3 (0.9-6.0)c 0.084 2.0 (0.8-5.4)c 0.163
Men
No 147 (96.1) 128 (94.1) 90 (90.0) 1.7 (1.0-2.8)a 0.058 1.7 (1.0-2.9)a 0.056
Yes 6 (3.9) 8 (5.9) 10 (10.0) 2.0 (0.8-5.2)b 0.145 2.0 (0.8-5.1)b 0.165
1.8 (0.7-4.7)c 0.244 1.8 (0.7-4.9)c 0.217
APRI S1.0
Women
No 258 (99.6) 159 (100.0) 63 (94.0) 6.3 (1.5-26.6)a 0.012 5.5 (1.3-23.6)a 0.022
Yes 1 (0.4) 0 (0.0) 4 (6.0) 4.6 (0.5-41.9)c 0.171 3.7 (0.4-33.5)c 0.248
Men
No 151 (98.7) 135 (99.3) 99 (99.0) 0.8 (0.2-3.0)a 0.774 0.8 (0.2-3.1)a 0.788
Yes 2 (1.3) 1 (0.7) 1 (1.0) 0.6 (0.1-4.6)b 0.663 0.6 (0.1-4.5)b 0.645
1.4 (0.1-22.1)c 0.827 1.3 (0.1-21.0)c 0.871
(continued on next page)
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Table 3 (continued )
Fatty liver OR (95% CI) p value Age-adjusted OR (95% CI) p value
Non Mild Significant
AST/ALT ratio S0.8
Women
No 12 (4.6) 24 (15.1) 21 (31.3) 0.3 (0.2-0.5)a <0.001 0.3 (0.2-0.5)a <0.001
Yes 247 (95.4) 135 (84.9) 46 (68.7) 0.2 (0.1-0.4)b <0.001 0.2 (1.0-0.4)b <0.001
0.4 (0.2-0.8)c 0.006 0.4 (0.2-0.7)c 0.004
Men
No 21 (13.7) 51 (37.5) 66 (66.0) 0.3 (0.2-0.4)a <0.001 0.3 (0.2-0.4)a <0.001
Yes 132 (86.3) 85 (62.5) 34 (34.0) 0.2 (0.1-0.3)b <0.001 0.2 (0.1-0.2)b <0.001
0.3 (0.2-0.5)c <0.001 0.3 (0.2-0.6)c <0.001
Abbreviations: ALT Z alanine aminotransferase, APRI Z aspartate aminotransferase-to-platelet ratio index, AST Z aspartate amino-
transferase, CI Z confidence interval, OR Z odds ratio, RR Z relative risk.
a ordered odds ratio.
b fatty liver vs. non fatty liver.
c significant fatty liver vs. mild fatty liver.
d men >31 IU/L and women >20 IU/L.
e sup>relative risk is derived from dividing the estimated risk of coronary heart disease by the comparative risk that is defined as the
average risk of coronary heart disease.
f APRI is derived from the formula of AST (IU/mL)/upper normal limit  100/platelet count (109/L).
158 C.-C. Wang et al.fibrosis and the severity of fatty liver on ultrasound could
not be confirmed in this study.
Our study had potential strengths and limitations. This
cohort consisted of consecutive individuals presenting for
health examination, so selection bias was avoided.
Furthermore, patients with viral hepatitis, the habit of
drinking (>140 g/wk) or known causes of hepatitis were
excluded to avoid confounding effects on the development
of hepatic steatosis, inflammation or fibrosis. This study
had three limitations. First, the calculated risk of CVD was
relative to the average risk of CVD in the population
included in the Framingham study. Although we acknowl-
edge that the average CVD risk might be different between
Western and Asian countries, we considered that the rela-
tive risks of the three groups in this study on the basis of the
reference age- and sex-matched population was still
representative of the relative possibility of CVD events.
Second, although NAFLD was diagnosed by ultrasound
examination rather than liver histology, it is thought that
ultrasound is commonly used in clinical practice to diagnose
NAFLD and that using invasive liver biopsy to assess the risk
of metabolic diseases in NAFLD patients may not be cost-
effective. Third, the “two hit” hypothesis of NAFLD
suggests that the accumulation of triglyceride in hepato-
cytes is the first hit, followed by the second hit of nec-
roinflammatory processes. Our result demonstrated the
association between hepatic steatosis and ALT elevation
(necroinflammation). Their causal relationship could not be
confirmed, however, because of the cross-sectional study
design. In addition, liver biopsy rather than APRI or AST/
ALT ratio is the gold standard for assessing the severity of
hepatic fibrosis. Further prospective studies with biopsy-
proven NAFLD patients are required to find out more about
the impact of steatosis on hepatic fibrosis.
In summary, the severity of fatty liver on ultrasound is
clinically useful for predicting the likelihood of metabolicdiseases, including diabetes mellitus, metabolic syndrome
and the risk of CVD.
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